Long-term outcome of patients with hereditary transthyretin V30M amyloidosis with polyneuropathy after liver transplantation

References

• Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952;75:408–27
   PubMed Web of Science ®Google Scholar
• Benson MD, Dwulet FE. Identification of carriers of a variant plasma prealbumin (transthyretin) associated with familial amyloidotic polyneuropathy type I. J Clin Invest 1985;75:71–75
   PubMed Web of Science ®Google Scholar
• Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011;10:1086–97
   PubMed Web of Science ®Google Scholar
• Ihse E, Rapezzi C, Merlini G, Benson MD, Ando Y, Suhr OB, Ikeda S, et al. Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid 2013;20:142–50
   PubMed Web of Science ®Google Scholar
• Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014;21:221–4
   PubMed Web of Science ®Google Scholar
• Beirão JM, Malheiro J, Lemos C, Beirão I, Costa P, Torres P. Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases. Amyloid 2015;22:117–22
   PubMed Web of Science ®Google Scholar
• Kristen AV, Aus dem Siepen F, Scherer K, Kammerer R, Andre F, Buss SJ, Bauer R, et al. Comparison of different types of cardiac amyloidosis by cardiac magnetic resonance imaging. Amyloid 2015;22:132–41
   PubMed Web of Science ®Google Scholar
• Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, Andersen O, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991;40:242–6
   PubMed Web of Science ®Google Scholar
• Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057–62
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, Gjertsen H, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 2007;7:2597–604
   PubMed Web of Science ®Google Scholar
• Okamoto S, Wixner J, Obayashi K, Ando Y, Ericzon BG, Friman S, Uchino M, et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients’ survival. Liver Transpl 2009;15:1229–35
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T, Ueda M, Obayashi K, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012;78:637–43
   PubMed Web of Science ®Google Scholar
• Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, Wallin BG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993;341:1113–16
   PubMed Web of Science ®Google Scholar
• Adams D, Samuel D, Goulon-Goeau C, Nakazato M, Costa PM, Feray C, Planté V, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000;123:1495–504
   PubMed Web of Science ®Google Scholar
• Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, Furtado E, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 2015;99:1847–54
   PubMed Web of Science ®Google Scholar
• Sakashita N, Ando Y, Haraoka K, Terazaki H, Yamashita T, Nakamura M, Takeya M. Severe congestive heart failure with cardiac liver cirrhosis 10 years after orthotopic liver transplantation for familial amyloidotic polyneuropathy. Pathol Int 2006;56:408–12
   PubMed Web of Science ®Google Scholar
• Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei YI, Koyama J, Kawamorita A, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 2007;7:235–42
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ando Y, Bernt Suhr O, Nakamura M, Sakashita N, Ohlsson PI, Terazaki H, et al. A new diagnostic procedure to detect unknown transthyretin (TTR) mutations in familial amyloidotic polyneuropathy (FAP). J Neurol Sci 2000;173:154–9
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ando Y, Katsuragi S, Nakamura M, Obayashi K, Haraoka K, Ueda M, et al. Muscular amyloid angiopathy with amyloidogenic transthyretin Ser50Ile and Tyr114Cys. Muscle Nerve 2005;31:41–5
   PubMed Web of Science ®Google Scholar
• Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411–23
   PubMed Web of Science ®Google Scholar
• Russo M, Mazzeo A, Stancanelli C, Di Leo R, Gentile L, Di Bella G, Minutoli F, et al. Transthyretin-related familial amyloidotic polyneuropathy: description of a cohort of patients with Leu64 mutation and late onset. J Peripher Nerv Syst 2012;17:385–90
   PubMed Web of Science ®Google Scholar
• Tashima K, Ando Y, Terazaki H, Yoshimatsu S, Suhr OB, Obayashi K, Yamashita T, et al. Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients. J Neurol Sci 1999;171:19–23
   PubMed Web of Science ®Google Scholar
• Ohya Y, Okamoto S, Tasaki M, Ueda M, Jono H, Obayashi K, Takeda K, et al. Manifestations of transthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation. Surg Today 2011;41:1211–18
   PubMed Web of Science ®Google Scholar
• Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Fujitake J, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry 2012;83:152–8
   PubMed Web of Science ®Google Scholar
• Ando Y, Yonehara T, Tanaka Y, Tashima K, Uchino M, Ando M. Early pacemaker implantation in patients with familial amyloidotic polyneuropathy. Muscle Nerve 1996;19:1640–1
   PubMed Web of Science ®Google Scholar
• Okamoto S, Yamashita T, Ando Y, Ueda M, Misumi Y, Obayashi K, Horibata Y, et al. Evaluation of myocardial changes in familial amyloid polyneuropathy after liver transplantation. Intern Med 2008;47:2133–7
   PubMed Web of Science ®Google Scholar
• Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology 2010;75:324–7
   PubMed Web of Science ®Google Scholar
• Gustafsson S, Ihse E, Henein MY, Westermark P, Lindqvist P, Suhr OB. Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation 2012;93:1017–23
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013;310:2658–67
   PubMed Web of Science ®Google Scholar
• Vinik EJ, Vinik AI, Paulson JF, Merkies IS, Packman J, Grogan DR, Coelho T. Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 2014;19:104–14
   PubMed Web of Science ®Google Scholar
• Cruz MW. Regional differences and similarities of familial amyloidotic polyneuropathy (FAP) presentation in Brazil. Amyloid 2012;19:65–7
   PubMed Web of Science ®Google Scholar
• Maia LF, Magalhães R, Freitas J, Taipa R, Pires MM, Osório H, Dias D, et al. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry 2015;86:159–67
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ando Y, Ueda M, Nakamura M, Okamoto S, Zeledon ME, Hirahara T, et al. Effect of liver transplantation on transthyretin Tyr114Cys-related cerebral amyloid angiopathy. Neurology 2008;70:123–8
   PubMed Web of Science ®Google Scholar
• Suhr OB, Friman S, Ericzon BG. Early liver transplantation improves familial amyloidotic polyneuropathy patients’ survival. Amyloid 2005;12:233–8
   PubMed Web of Science ®Google Scholar
• Obayashi K, Ueda M, Oshima T, Kawahara S, Misumi Y, Yamashita T, Jono H, et al. Pathological changes long after liver transplantation in a familial amyloidotic polyneuropathy patient. BMJ Case Rep 2012;2012:piibcr2012006593. doi: 10.1136/bcr-2012-006593
   PubMedGoogle Scholar
• Wilczek HE, Larsson M, Ericzon BG, FAPWTR. Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid 2011;18:193–5
   PubMed Web of Science ®Google Scholar
• Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson’s disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008;23:2194–201
   PubMed Web of Science ®Google Scholar
• Ando Y, Ueda M. Diagnosis and therapeutic approaches to transthyretin amyloidosis. Curr Med Chem 2012;19:2312–23
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79:785–92
   PubMed Web of Science ®Google Scholar
• Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013;369:819–29
   PubMed Web of Science ®Google Scholar